Physicians

Departments / Divisions

• Surgery / Urology
• Pathology

Address
DUMC 2626
Durham, NC 27710

Appointment Telephone
919-668-8108

Office Telephone
919-668-5946

Fax Telephone
919-668-7093

Training

• MD, University of California–Davis School of Medicine, 1997

Residency

• General Surgery, University of California–Los Angeles Medical Center, 1997-1999
• Urology, University of California–Los Angeles Medical Center, 1999-2003

Fellowship

• Urologic Oncology, Johns Hopkins Hospital (Maryland), 2003-2005

Clinical Interests
Prostate cancer, benign prostatic hyperplasia, and other prostate diseases; GreenLight laser prostatectomy; radical prostatectomy; TURP; button TURP

Research Interests
Prostate cancer
Obesity
Nutrition
Diet
Outcomes and database analyses
Statistical modeling
risk stratification
PSA
Biomarkers

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Amgen, Inc.
• AstraZeneca
• Bayer Schering Pharma AG
• Dendreon Corporation
• Janssen Pharmaceuticals (Johnson & Johnson)
• Medivation, Inc.
• Mitomics
• Oncocell MDx

Representative Publications
Freedland, SJ; Giovannucci, E; Platz, EA. Are findings from studies of obesity and prostate cancer really in conflict?. Cancer Causes and Control. 2006;17:5-9. (2006) Abstract

Freedland, SJ; Kane, CJ; Amling, CL; Aronson, WJ; Presti, JC; Terris, MK; SEARCH Database Study Group. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. Journal of Urology. 2006;175:1298-1302. (2006) Abstract

Freedland, SJ; Partin, AW. Prostate-specific antigen: update 2006. Urology. 2006;67:458-460. (2006) Abstract

Freedland, SJ; Platz, EA; Presti, JC; Aronson, WJ; Amling, CL; Kane, CJ; Terris, MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. Journal of Urology. 2006;175:500-504. (2006) Abstract

Makarov, DV; Humphreys, EB; Mangold, LA; Walsh, PC; Partin, AW; Epstein, JI; Freedland, SJ. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. Journal of Urology. 2006;176:554-558. (2006) Abstract

Nielsen, ME; Han, M; Mangold, L; Humphreys, E; Walsh, PC; Partin, AW; Freedland, SJ. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. Journal of Urology. 2006;176:515-519. (2006) Abstract

Freedland, SJ. Obesity and prostate cancer: a growing problem. Clinical Cancer Research. 2005;11:6763-6766. (2005) Abstract

Freedland, SJ; Aronson, WJ. Obesity and prostate cancer. Urology. 2005;65:433-439. (2005) Abstract

Freedland, SJ; Grubb, KA; Yiu, SK; Humphreys, EB; Nielsen, ME; Mangold, LA; Isaacs, WB; Partin, AW. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. Journal of Urology. 2005;174:919-922. (2005) Abstract

Freedland, SJ; Grubb, KA; Yiu, SK; Nielsen, ME; Mangold, LA; Isaacs, WB; Epstein, JI; Partin, AW. Obesity and capsular incision at the time of open retropubic radical prostatectomy. Journal of Urology. 2005;174:1798-1801. (2005) Abstract

Freedland, SJ; Haffner, MC; Landis, PK; Saigal, CS; Carter, HB. Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology. 2005;65:1131-1136. (2005) Abstract

Freedland, SJ; Humphreys, EB; Mangold, LA; Eisenberger, M; Dorey, FJ; Walsh, PC; Partin, AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA: Journal of the American Medical Association. 2005;294:433-439. (2005) Abstract

Freedland, SJ; Isaacs, WB. Explaining racial differences in prostate cancer in the United States: sociology or biology?. The Prostate. 2005;62:243-252. (2005) Abstract

Freedland, SJ; Isaacs, WB; Mangold, LA; Yiu, SK; Grubb, KA; Partin, AW; Epstein, JI; Walsh, PC; Platz, EA. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clinical Cancer Research. 2005;11:2883-2888. (2005) Abstract

Freedland, SJ; Isaacs, WB; Platz, EA; Terris, MK; Aronson, WJ; Amling, CL; Presti, JC; Kane, CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. Journal of Clinical Oncology. 2005;23:7546-7554. (2005) Abstract

Freedland, SJ; Mangold, LA; Walsh, PC; Partin, AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. Journal of Urology. 2005;174:1276-1281. (2005) Abstract

Freedland, SJ; Terris, MK; Platz, EA; Presti, JC. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005;66:108-113. (2005) Abstract

Haffner, MC; Landis, PK; Saigal, CS; Carter, HB; Freedland, SJ. Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology. 2005;66:371-376. (2005) Abstract

Freedland, SJ; Aronson, WJ; Kane, CJ; Presti, JC; Amling, CL; Elashoff, D; Terris, MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. Journal of Clinical Oncology. 2004;22:446-453. (2004) Abstract

Freedland, SJ; Aronson, WJ; Kane, CJ; Terris, MK; Presti, JC; Trock, B; Amling, CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004;101:748-753. (2004) Abstract

Freedland, SJ; Mangold, LA; Epstein, JI; Partin, AW. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology. 2004;63:887-891. (2004) Abstract

Freedland, SJ; Partin, AW; Epstein, JI; Walsh, PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer. 2004;100:1646-1649. (2004) Abstract

Freedland, SJ; Presti, JC; Kane, CJ; Aronson, WJ; Terris, MK; Dorey, F; Amling, CL; SEARCH Database Study Group. Do younger men have better biochemical outcomes after radical prostatectomy?. Urology. 2004;63:518-522. (2004) Abstract

Freedland, SJ; Terris, MK; Csathy, GS; Kane, CJ; Amling, CL; Presti, JC; Dorey, F; Aronson, WJ; Search Database Study Group. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. Journal of Urology. 2004;171:2215-2220. (2004) Abstract

Freedland, SJ; Terris, MK; Presti, JC; Amling, CL; Kane, CJ; Trock, B; Aronson, WJ; Search Database Study Group. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. Journal of Urology. 2004;172:520-524. (2004) Abstract

Ngo, TH; Barnard, RJ; Anton, T; Tran, C; Elashoff, D; Heber, D; Freedland, SJ; Aronson, WJ. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Research. 2004;64:1252-1254. (2004) Abstract

Okotie, OT; Aronson, WJ; Wieder, JA; Liao, Y; Dorey, F; DeKERNION, JB; Freedland, SJ. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. Journal of Urology. 2004;171:2260-2264. (2004) Abstract

Freedland, SJ; Aronson, W; Presti, JC; Kane, CJ; Terris, MK; Elashoff, D; Amling, CL; SEARCH Database Study Group. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. Journal of Urology. 2003;169:2142-2146. (2003) Abstract

Freedland, SJ; Aronson, WJ; Terris, MK; Kane, CJ; Amling, CL; Dorey, F; Presti, JC; SEARCH Database Study Group. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Journal of Urology. 2003;169:2136-2141. (2003) Abstract

Freedland, SJ; Presti, JC; Amling, CL; Kane, CJ; Aronson, WJ; Dorey, F; Terris, MK; SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741. (2003) Abstract

Freedland, SJ; Presti, JC; Terris, MK; Kane, CJ; Aronson, WJ; Dorey, F; Amling, CL; SEARCH Database Study Group. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Journal of Urology. 2003;169:2129-2135. (2003) Abstract

Freedland, SJ; Sutter, ME; Dorey, F; Aronson, WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365-369. (2003) Abstract

Freedland, SJ; Amling, CL; Dorey, F; Kane, CJ; Presti, JC; Terris, MK; Aronson, WJ; Shared Equal Access Regional Cancer Hospital Database Study Group. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674. (2002) Abstract

Freedland, SJ; Csathy, GS; Dorey, F; Aronson, WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. Journal of Urology. 2002;167:516-520. (2002) Abstract

Freedland, SJ; Jalkut, M; Dorey, F; Sutter, ME; Aronson, WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000;56:87-91. (2000) Abstract

Freedland, SJ; Sutter, ME; Naitoh, J; Dorey, F; Csathy, GS; Aronson, WJ. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology. 2000;55:387-390. (2000) Abstract